Manufacturers report positive results for baricitinib in atopic dermatitis
In the Phase III FREEZE-AD4 trial baricitinib was found to be superior to placebo for achievement of 75% or greater improvement on the Eczema Area and Severity Index (EASI) at Week 16.
Source:
PharmaLive